Digestive Diseases

Digestive Diseases is a gastroenterology journal founded in 1983 whose imprint and copyright rest with S. Karger AG of Basel, while the Oxford University Press platform carries the content, publishing clinical work on diagnosis and treatment six times a year with a 2025 Journal Impact Factor of 2.4 and a CiteScore of 5.3.《消化疾病》是 1983 年创刊的消化病学期刊，出版方与著作权归瑞士 S. Karger AG，内容由牛津大学出版社的平台承载，每年出 6 期，刊载胃肠疾病诊断与治疗方向的临床论文，2025 年期刊影响因子为 2.4，CiteScore 为 5.3。

Scope

• The remit is set out on the publisher page as the latest in diagnosis and treatment of gastrointestinal disorders, which places clinical management at the centre of the title.出版方页面把办刊宗旨写作胃肠疾病诊断与治疗的最新进展，临床处置由此处在刊物的中心。
• Ten sections organise the subject, from esophagus, functional GI diseases, stomach and duodenum and small and large bowel, through liver, pancreas and microbiota, to endoscopy and imaging, nutrition and probiotics and clinical pharmacology and therapeutics.学科分为 10 个栏目，依次是食管，功能性胃肠病，胃与十二指肠，小肠与大肠，肝，胰，微生物组，内镜与影像，营养与益生菌，以及临床药理学与治疗学。
• Research articles are original reports that typically run to 5,000 words with four to eight tables or figures, and authors are asked to follow the EQUATOR guidance that fits their design.研究论文是原创报告，篇幅通常 5000 词，配 4 至 8 个表或图，作者须按与自己研究设计对应的 EQUATOR 规范写作。
• Reviews take the same length and the same allowance of display items, with the added demand that the evidence be weighed critically and that the piece end on a definite conclusion.综述的篇幅与图表额度与此相同，另加两条要求，证据须经批判性权衡，全文要落到明确结论上。
• Systematic reviews are built on introduction, methods, results and discussion, and the submission has to carry a completed PRISMA checklist alongside the manuscript.系统综述按引言，方法，结果，讨论四段搭建，投稿时须一并交上填好的 PRISMA 清单。
• Brief reports carry short or fast-turnaround accounts of original data, and guideline documents form a category of their own rather than being folded into reviews.简报承载篇幅短或需快速刊出的原创数据，指南类文件单列一类，不并入综述。
• Editorials run to about 1,000 words with no more than three display items, and they are written by the editors or by members of the editorial board.社论约 1000 词，图表至多 3 个，由编辑或编委执笔。
• Endoscopy and imaging papers face a tighter ceiling of 1,500 words and 15 references, a limit that pushes the argument onto the image or the clip itself.内镜与影像类稿件受更紧的上限约束，1500 词，参考文献至多 15 条，这一额度把论证的担子压到图像或视频上。
• Video may run to five gigabytes and needs a legend, and the frames must be free of brand marks and conference logos, with any earlier showing at a meeting declared in the cover letter.视频可到 5 Gb，须配图注，画面不得带品牌标识与会议标志，若此前在会议上放映过，须在投稿信里说明。
• Randomised trials submit a CONSORT checklist and observational studies a STROBE one, and a manuscript that arrives without the required list is returned to its authors.随机对照试验交 CONSORT 清单，观察性研究交 STROBE 清单，缺少所需清单的稿件会退回作者。
• Work on human subjects needs approval from an institutional review board or an ethics committee and written informed consent, with parents or guardians signing for minors.以人为对象的研究须获机构审查委员会或伦理委员会批准，并取得书面知情同意，未成年人由父母或监护人代签。
• A clinical trial must give its registration number at the close of the abstract, in line with ICMJE policy, and the number and link appear again where the acronym first shows.临床试验须按 ICMJE 的规定在摘要末尾给出注册号，缩写首次出现处还要再标一遍注册号与链接。
• Keywords sit below the abstract and are best drawn from the MeSH vocabulary of Index Medicus, while words already used in the title are discouraged.关键词列在摘要之下，最好取自 Index Medicus 的 MeSH 词表，与题名重复的词则不主张再用。
• A graphical abstract is encouraged for every article type and travels as a separate file named graphical_abstract, appearing online, in the PDF and in the table of contents.各类稿件都鼓励配图文摘要，单独成文件并以「graphical_abstract」命名，随文在线发表，也排进 PDF 与目录。
• Audio in MP3 and video in MP4 are accepted under numbered file names, files parked on a third-party site are not, and any background music has to be cleared.音频用 MP3，视频用 MP4，按编号命名后可以提交，挂在第三方站点的文件不予接受，背景音乐须已清权。

History

• The first volume is dated 1983 and stands in Crossref as volume 1 with issues 1 and 2 combined, and every year since has added exactly one volume.第 1 卷标注的年份是 1983 年，在 Crossref 中登记为第 1 卷第 1 与第 2 期合刊，此后每一年正好增加一卷。
• Volume 44 carries the 2026 issues, and that count runs back without a gap to the opening year, with no relaunch or renumbering to interrupt it.2026 年的各期编为第 44 卷，卷次由此一路回溯到创刊那年而中间不断，也没有改版或重编号来打断这条线。
• The earliest deposits sit under the 10.1159 DOI prefix, which belongs to Karger, so the founding metadata went in from the publisher rather than being assembled later.最早的登记条目落在 10.1159 这一 DOI 前缀之下，前缀属于 Karger，创刊元数据由出版方自己存缴，并非后来拼凑。
• Ownership has stayed put. The site that carries the journal now sits on academic.oup.com, yet the footer still reads Copyright © 2026 Karger, and the disclaimer names S. Karger AG before Oxford University Press.归属始终未变。如今承载该刊的站点在 academic.oup.com 之下，页脚仍署 Copyright © 2026 Karger，免责声明先列 S. Karger AG，再列牛津大学出版社。
• Six issues appear each year in print and online, as the author guidelines put it, while the NLM record still lists four issues a year from 2000.作者指南写明每年在线与印刷各出 6 期，NLM 的连续出版物记录却仍标着 2000 年起每年 4 期。
• Volume 43 closed in 2025 with issues 4 to 6 and volume 44 opened in 2026 with issues 1 to 3, so the six issues straddle the year boundary.第 43 卷在 2025 年以第 4 至第 6 期收尾，第 44 卷在 2026 年以第 1 至第 3 期开卷，6 期跨在年界两侧。
• MEDLINE coverage is recorded from volume 4 issue 1 of 1986, a date that has been read as the founding year often enough to be worth spelling out.MEDLINE 的收录起点记为 1986 年第 4 卷第 1 期，这个年份屡屡被读成创刊年，值得专门说清。
• The title sits in the Science Citation Index Expanded and in Index Medicus, and a citation total near 3,064 with a half-life of 9.1 years points to a slow-burning clinical literature.该刊在 Science Citation Index Expanded 与 Index Medicus 之中，总被引接近 3064 次，被引半衰期 9.1 年，所载临床文献的引证周期偏长。
• Output is modest at roughly 54 papers a year, which suits a journal that prints reviews and clinical syntheses more often than large trial reports.年发文量不大，约 54 篇，这与一份多登综述与临床综合、少登大型试验报告的刊物相称。
• The impact factor read 3.421 in 2022, dropped to 2 in 2023, edged up to 2.1 in 2024 and reached 2.4 in 2025, so the annual and five-year figures now sit level.影响因子 2022 年为 3.421，2023 年降到 2，2024 年回到 2.1，2025 年为 2.4，当年值与五年值如今持平。
• Clarivate places the title 91st of 153 in gastroenterology and hepatology, which corresponds to the third quartile, while Scopus ranks it 46th of 176 in gastroenterology.Clarivate 把该刊排在胃肠病学与肝病学类 153 种期刊的第 91 位，对应第三四分位，Scopus 的胃肠病学排名则是 176 种中的第 46 位。
• Open access is optional, the gold share has reached 31.44 percent, and a Read and Publish arrangement covers corresponding authors whose main post is at a qualifying institution.开放获取为可选项，金色 OA 占比已达 31.44%，Read and Publish 协议覆盖主要任职单位属合资格机构的通讯作者。
• That arrangement requires the corresponding author to hold a qualifying institution at the point of submission, and a later switch of corresponding author to claim the funding is refused.该协议要求通讯作者在投稿当时即任职于合资格机构，投稿之后再改通讯作者以套取资助的请求会被拒绝。
• Once the licence is signed the accepted manuscript goes onto the Advance articles page within a week and is later replaced by the version of record, and no paper may be pulled once published.出版协议签署后，录用稿一周内上到 Advance articles 页面，随后被正式版本替换，论文一经发表不得撤下。

Editors

• Peter Malfertheiner is editor-in-chief, listed with the University of Munich and the University of Magdeburg, and the final decision on every manuscript rests with him.主编是 Peter Malfertheiner，编委页把他列在德国的慕尼黑大学（University of Munich）与马格德堡大学（University of Magdeburg），每篇稿件的终裁由他作出。
• Carolina Malagelada Prats works from the Vall d'Hebron Institut de Recerca in Barcelona, Jaroslaw Regula from the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw, and Luigi Ricciardiello from the MD Anderson Cancer Center in Houston.三位执行编辑分处三地，Carolina Malagelada Prats 在巴塞罗那的 Vall d'Hebron Institut de Recerca，Jaroslaw Regula 在华沙的 Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology，Luigi Ricciardiello 在休斯敦的 MD Anderson Cancer Center。
• Thirty associate editors divide the field by organ and by system, so a manuscript on the pancreas reaches a pancreas reader and one on microbiota reaches a microbiota reader.30 位副编辑按器官与系统分区，胰腺稿件交胰腺方向的副编辑，微生物组稿件交微生物组方向的副编辑。
• The groups run from upper gastrointestinal tract and esophagus through stomach and duodenum, functional gastrointestinal disease and general gastroenterology, then liver, pancreas and microbiota, and on to endoscopy and imaging, nutrition and probiotics and clinical pharmacology.分组依次为上消化道，食管，胃与十二指肠，功能性胃肠病，普通消化病学，肝，胰，微生物组，内镜与影像，营养与益生菌，临床药理学与治疗学。
• Board groupings and the ten journal sections do not line up exactly, since the associate editors work under General Gastroenterology while the author guidelines carry Small and Large Bowel.编委分组与作者指南的 10 个栏目并不完全对齐，副编辑按普通消化病学归组，作者指南列的却是小肠与大肠。
• The ten board members sit in Colorado, Bologna, Hyderabad, Tokyo, Bangkok, Rome, Munich, Kanagawa and Lucknow, with Bologna holding two seats.10 位编委分布在科罗拉多，博洛尼亚，海得拉巴，东京，曼谷，罗马，慕尼黑，神奈川与勒克瑙，博洛尼亚占两席。
• Associate editors reach much further, with posts in Serbia, Thailand, Singapore, Italy, Latvia, Greece, Australia, Brazil, South Africa, Taiwan, Britain, Spain, Nigeria and Malta.副编辑的分布更广，任职地包括塞尔维亚，泰国，新加坡，意大利，拉脱维亚，希腊，澳大利亚，巴西，南非，台湾，英国，西班牙，尼日利亚与马耳他。
• Review is single anonymized under the ANSI/NISO terminology, so the reviewers know who wrote the paper while the authors never learn who reviewed it.评审按 ANSI/NISO 的标准术语属单盲，审稿人知道作者是谁，作者始终不知道审稿人是谁。
• The editor-in-chief screens each submission, a handling editor runs the review and recommends, and the editor-in-chief takes the final decision, with at least two reviewers normally involved.主编先做初评，责任编辑主持评审并给出建议，最后由主编裁定，通常至少两位审稿人参与。
• Author-suggested reviewers are not considered, and the guidelines state that refusal outright instead of leaving the choice to editorial discretion.作者推荐的审稿人一律不予采纳，指南把这条拒绝写在明面上，不交由编辑自行斟酌。
• Review information is never published and no commenting is offered after publication, with an exception noted where an author also sits on the editorial board.评审信息不予公布，文后也不设在线评论，唯一例外是作者本人也在编委之列。
• Submissions go through ScholarOne, the publisher page quotes an average of eight weeks to a final decision, and the journal follows COPE guidance on misconduct.投稿走 ScholarOne 系统，出版方页面标注平均 8 周出最终决定，期刊按 COPE 的准则处理学术不端。